Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Triple-Negative Breast Carcinoma”

73 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 73 results

Testing effectiveness (Phase 2)Looking for participantsNCT07189871
What this trial is testing

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Who this might be right for
Castration-Resistant Prostate Cancer (CRPC)Colorectal CancerNSCLC (Non-small Cell Lung Cancer)+7 more
Radiopharm Theranostics, Ltd 61
Early research (Phase 1)Looking for participantsNCT06999187
What this trial is testing

DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Who this might be right for
Triple Negative Breast CancerHER2-negative Breast CancerNon Small Cell Lung Cancer+9 more
Dren Bio 96
Early research (Phase 1)Looking for participantsNCT05768932
What this trial is testing

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

Who this might be right for
Advanced Solid TumorTNBC - Triple-Negative Breast CancerGastric Cancer+1 more
SillaJen, Inc. 260
Testing effectiveness (Phase 2)Ended earlyNCT04216472
What this trial is testing

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8+19 more
M.D. Anderson Cancer Center 6
Testing effectiveness (Phase 2)Ended earlyNCT04095689
What this trial is testing

Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerAnthracycline-refractory TNBC
The Methodist Hospital Research Institute 8
Early research (Phase 1)Study completedNCT02071862
What this trial is testing

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Who this might be right for
Solid TumorsTriple-Negative Breast CancerNon Small Cell Lung Cancer+7 more
Calithera Biosciences, Inc 210
Early research (Phase 1)Ended earlyNCT03861403
What this trial is testing

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Who this might be right for
Solid TumorsAdvanced Triple Negative Breast CancerAdvanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer+2 more
Leap Therapeutics, Inc. 10
Early research (Phase 1)Ended earlyNCT04348916
What this trial is testing

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

Who this might be right for
CancerMelanomaSolid Tumor+7 more
Oncorus, Inc. 66
Early research (Phase 1)Ended earlyNCT05274451
What this trial is testing

Investigate LYL797 in Adults With Solid Tumors

Who this might be right for
Triple Negative Breast CancerTNBC - Triple-Negative Breast CancerNon-small Cell Lung Cancer+20 more
Lyell Immunopharma, Inc. 57
Testing effectiveness (Phase 2)Study completedNCT01677455
What this trial is testing

An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer

Who this might be right for
Breast CancerHER-2 Positive Breast CancerTriple Negative Breast Cancer+1 more
Synta Pharmaceuticals Corp. 51
Testing effectiveness (Phase 2)Active Not RecruitingNCT04837209
What this trial is testing

Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

Who this might be right for
Breast CancerTriple Negative Breast Cancer
Massachusetts General Hospital 32
Early research (Phase 1)Study completedNCT03739931
What this trial is testing

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Who this might be right for
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or LymphomaDose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
ModernaTX, Inc. 134
Early research (Phase 1)Looking for participantsNCT05989828
What this trial is testing

A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
University of Southern California 20
Testing effectiveness (Phase 2)UnknownNCT03044730
What this trial is testing

Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery

Who this might be right for
Estrogen Receptor NegativeHER2/Neu NegativeProgesterone Receptor Negative+7 more
Northwestern University 30
Testing effectiveness (Phase 2)Looking for participantsNCT06532812
What this trial is testing

TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer

Who this might be right for
Breast CancerBreast CarcinomaBreast Cancer Metastatic+1 more
Essen Biotech 85
Early research (Phase 1)Study completedNCT01837602
What this trial is testing

CMet CAR RNA T Cells Targeting Breast Cancer

Who this might be right for
Metastatic Breast CancerTriple Negative Breast Cancer
University of Pennsylvania 6
Early research (Phase 1)Study completedNCT02485119
What this trial is testing

Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies

Who this might be right for
Neoplasms
Bayer 12
Testing effectiveness (Phase 2)WithdrawnNCT02161679
What this trial is testing

Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer

Who this might be right for
Triple-negative Breast Cancer
Gilead Sciences
Testing effectiveness (Phase 2)Study completedNCT03752723
What this trial is testing

Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)

Who this might be right for
Triple Negative Breast Cancer
Genexine, Inc. 84
Early research (Phase 1)Study completedNCT01520389
What this trial is testing

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

Who this might be right for
Advanced Solid TumorsColorectal CancerSquamous Cell Head and Neck Cancer+2 more
Merrimack Pharmaceuticals 112
Next Page